Maze Therapeutics, Inc. Common Stock

Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and sold 7,500 shares for approximately $190,000 on April 29, 2026, reducing his direct holdings by 41.66%. The sale was part of a Rule 10b5-1 trading plan and should not be interpreted as a signal about his conviction in the company. Maze reported positive phase 2...

Maze Therapeutics (MAZE) priced an underwritten offering of 5.54 million shares at $23.50 per share, plus pre-funded warrants, raising $150 million in gross proceeds. The company plans to use net proceeds to advance development of MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, with expected cas...

Maze Therapeutics' Chief Medical Officer Harold Bernstein sold all 15,000 of his direct shares (~$442,000) on April 1, 2026, as part of a pre-established Rule 10b5-1 trading plan adopted in September 2025. While the complete disposition of direct holdings might appear concerning, the sale was executed through a planned trading arrangement designe...

Harold Bernstein, President and Chief Medical Officer of Maze Therapeutics, exercised and sold 30,000 shares on March 10, 2026, generating ~$1.51 million. The sale was part of a pre-arranged Rule 10b5-1 trading plan. Despite eliminating his direct equity ownership, Bernstein retains 267,407 stock options. The transaction occurs less than a month ...

Harold Bernstein, Chief Medical Officer of Maze Therapeutics, exercised and sold 15,000 shares for approximately $690,300 on February 2, 2026, fully divesting his direct ownership. The sale was part of a pre-arranged 10b5-1 trading plan and should not concern investors. Despite the insider sale, Bernstein retains nearly 300,000 stock options, and...